David Happel - 19 Feb 2026 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
President & CEO, Director
Signature
/s/ Elizabeth Rozek, Attorney-in-Fact
Issuer symbol
SGMT
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 16:41:03 UTC
Previous filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Happel David President & CEO, Director SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO /s/ Elizabeth Rozek, Attorney-in-Fact 20 Feb 2026 0001623567

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMT Series A Common Stock Award $0 +128,000 +19% $0.000000 805,621 19 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Stock Option (Right to Buy) Award $0 +256,000 $0.000000 256,000 19 Feb 2026 Series A Common Stock 256,000 $5.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.